These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 17577033)

  • 1. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
    Filipazzi P; Valenti R; Huber V; Pilla L; Canese P; Iero M; Castelli C; Mariani L; Parmiani G; Rivoltini L
    J Clin Oncol; 2007 Jun; 25(18):2546-53. PubMed ID: 17577033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
    Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
    Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
    Valenti R; Huber V; Filipazzi P; Pilla L; Sovena G; Villa A; Corbelli A; Fais S; Parmiani G; Rivoltini L
    Cancer Res; 2006 Sep; 66(18):9290-8. PubMed ID: 16982774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
    Tarhini AA; Butterfield LH; Shuai Y; Gooding WE; Kalinski P; Kirkwood JM
    J Immunother; 2012; 35(9):702-10. PubMed ID: 23090079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
    Lipson EJ; Sharfman WH; Chen S; McMiller TL; Pritchard TS; Salas JT; Sartorius-Mergenthaler S; Freed I; Ravi S; Wang H; Luber B; Sproul JD; Taube JM; Pardoll DM; Topalian SL
    J Transl Med; 2015 Jul; 13():214. PubMed ID: 26143264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
    Serafini P; Carbley R; Noonan KA; Tan G; Bronte V; Borrello I
    Cancer Res; 2004 Sep; 64(17):6337-43. PubMed ID: 15342423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
    Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
    Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
    [No Abstract]   [Full Text] [Related]  

  • 9. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
    Eton O; Ross MI; East MJ; Mansfield PF; Papadopoulos N; Ellerhorst JA; Bedikian AY; Lee JE
    J Transl Med; 2010 Jan; 8():9. PubMed ID: 20109236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma.
    Yuan XK; Zhao XK; Xia YC; Zhu X; Xiao P
    J Int Med Res; 2011; 39(4):1381-91. PubMed ID: 21986138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
    Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
    J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
    Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
    J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
    J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Lachmann G; Kurth J; von Haefen C; Yuerek F; Wernecke KD; Spies C
    Int J Med Sci; 2017; 14(4):367-375. PubMed ID: 28553169
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
    Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
    Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
    Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Ross MI; Haas NB; Grosh WW; Boisvert ME; Kirkwood JM; Chianese-Bullock KA
    Clin Cancer Res; 2009 Nov; 15(22):7036-44. PubMed ID: 19903780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
    Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
    Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.